Antibody for selective inhibition of T-cell responses
AssigneeTolera Therapeutics, Inc.
InventorsDaniel R. Getts, James J. Herrmann, John J. Puisis, Frank J. Fokta
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions, methods, and assays for treating an inflammatory and/or autoimmune disease, and/or transplanted tissue rejection using anti-αβ TCR antibodies and antibody fragments. Anti-αβ TCR antibodies are antibodies which bind to a αβ TCR. Anti-αβ TCR antibodies produced by the hybridoma TOL101 MCB are also provided. Methods for treatment of an inflammatory disease, an autoimmune disease and for tissue transplant rejection using therapeutic dosing regimen of anti-αβ TCR antibodies and antibody fragments and for upregulating the numbers of Treg T-cells are also provided.
Claims2
An isolated antibody produced by the hybridoma TOL101 MCB deposited with the ATCC under the accession number PTA-13293.
Dependencies are inferred from the claim text.